Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Area of Science:

• Genomics
• Cancer Biology
• Synthetic Lethality

Background:

• CRISPR/Cas9 screens identify synthetic lethal targets for genetic diseases like BRCA1-mutated cancers.
• Patient mutations often cause hypomorphic phenotypes, unlike the full protein deficiency used in screens.
• Understanding these nuances is crucial for effective therapeutic target identification.

Purpose of the Study:

• To investigate the genetic vulnerabilities of two BRCA1 missense mutations.
• To compare these vulnerabilities to a BRCA1-depleted setting.
• To determine if mutation type affects synthetic lethal interaction screening.

Main Methods:

• Utilized CRISPR/Cas9 genome-wide synthetic lethality screens.
• Studied two hypomorphic BRCA1 missense mutations (I26A and R1699Q).
• Compared mutant cells to BRCA1-depleted and wild-type cells.

Main Results:

• BRCA1^I26A mutation showed vulnerabilities similar to wild-type BRCA1 cells.
• BRCA1^R1699Q mutation exhibited phenotypes resembling BRCA1-deficient cells.
• BRCA1^R1699Q cells uniquely displayed vulnerability to NDE1 loss, causing genomic instability.

Conclusions:

• Differentiating between patient-derived BRCA1 mutations is essential for accurate therapeutic target assessment.
• Hypomorphic mutations can present distinct genetic vulnerabilities compared to full deficiency.
• NDE1 loss represents a potential therapeutic target specifically for BRCA1^R1699Q-mutated cancers.